Author's reply: statins and cholesterol gallstones: what we know, thought we knew and hope to gain

Author： Ahmed Mohamed H   Connolly Vincent   Hamad Mahir A  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.13, Iss.9, 2012-06, pp. : 1385-1386

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Idarucizumab: What Should We Know?

By  

Current Drug Targets, Vol. 19, Iss. 1, 2018-01 ,pp. : 81-88

Bentham Science Publishers

Access to resources Recommend Favorite

Assays and applications in warfarin metabolism: what we know, how we know it and what we need to know

By Jones Drew R   Miller Grover P  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 7, 2011-07 ,pp. : 857-874

Informa Healthcare

Access to resources Recommend Favorite

Adenosine Receptors: What We Know and What We are Learning

By  

Current Topics in Medicinal Chemistry, Vol. 10, Iss. 9, 2010-06 ,pp. : 860-877

Bentham Science Publishers

Access to resources Recommend Favorite

What we know and what we think we know: An editor's perspective on a charged debate

By Khuri Fadlo R.  

Cancer, Vol. 121, Iss. 1, 2015-01 ,pp. : 4-5

Blackwell Publishing

Access to resources Recommend Favorite

WHAT WE KNOW AND WHAT WE NEED TO KNOW ABOUT DEVELOPMENTAL ALUMINUM TOXICITY

By Golub Mari S.   Domingo Jose L.  

Journal of Toxicology and Environmental Health, Vol. 48, Iss. 6, 1996-08 ,pp. : 585-598

Taylor & Francis Ltd

Access to resources Recommend Favorite